Pill Pushers' Paperwork: FDA Seeks Input on Drug Distributor Checks
Published Date: 2/20/2026
Notice
Summary
The FDA wants your thoughts on how it collects info about groups that check and license drug wholesalers and delivery companies. This helps keep medicine safe and the supply chain strong. If you’re involved or interested, send your comments by April 21, 2026—no cost to join, just your voice!
Analyzed Economic Effects
4 provisions identified: 0 benefits, 4 costs, 0 mixed.
Third Parties Can Drive Licenses
FDA will allow approved third-party organizations (AOs) to perform licensure reviews and inspections for wholesale drug distributors and third-party logistics providers (3PLs). FDA says it can rely on AO reports when deciding whether to issue a license under sections 583(c) and 584(d)(2)(A) of the FD&C Act.
Paperwork Burden Hours Estimated
FDA estimates the annual reporting burden as 15 respondents, 279 total responses, and 1,386 total hours. FDA also estimates recordkeeping as 18 recordkeepers, 102 total records, and 204 total hours per year for these collections under 21 CFR part 205.
7-Day AO Inspection Report Deadline
When an AO inspects a 3PL facility, the AO must provide FDA with an inspection report within 7 days after completion of the inspection. FDA will use the AO's report to make the final licensing decision for the facility.
AOs Must Keep Records Five Years
FDA proposes that an approved organization (AO) must maintain certain records for at least 5 years and make those records readily available to FDA upon request. This recordkeeping requirement applies as a condition of keeping AO approval.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20063, Request for Nominations for Voting Members of Food and Drug Administration Advisory Committees
The FDA is looking for smart, qualified people to join its advisory committees and help make important decisions about food and drugs. If you have the right skills, you can apply anytime, but get your nomination in by November 30, 2026, for the best chance at current openings. This is a great chance to influence public health without any cost to you!
Previous / Next Documents
Previous: 2026-03332, Agency Information Collection Activities; Proposed Collection; Comment Request; Hazard Analysis and Critical Control Point Procedures for the Safe and Sanitary Processing and Importing of Juice
The FDA wants to hear from juice makers and importers about their rules for keeping juice safe and clean using special safety checks called HACCP. They’re asking for comments by April 21, 2026, to help decide if they should keep or change these rules. This affects anyone who processes or imports fruit and vegetable juices and helps keep your juice safe without adding extra costs.
Next: 2026-03334, Self-Regulatory Organizations; Cboe Exchange, Inc.; Notice of Filing and Immediate Effectiveness of a Proposed Rule Change To Make a Number of Technical, Non-Substantive Changes to Its Rulebook
Cboe Exchange is updating its rulebook with a bunch of small, technical fixes that don’t change any big rules. These tweaks help keep everything clear and running smoothly for traders and the Exchange itself. The changes took effect right away on February 10, 2026, and won’t cost anyone extra or change how trading works.